Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 74

Sort by

Sort Order Select

Journal Articles

Prevalence of BTK and PLCG2 Mutations in BTK Inhibitor Treated CLL Patients Who Experience Disease Progression: A Meta-Analysis

Stefano Molica, David Allsup, Diana Giannarelli

Blood (2024) 144 (Supplement 1): 4630.

https://doi.org/10.1182/blood-2024-200896

Published: 2024

Journal Articles

Targeted Agents in Chronic Lymphocytic Leukemia (CLL): Advancements in Overall Survival Outcomes?

Stefano Molica, Tait D. Shanafelt, David Allsup, Diana Giannarelli

Blood (2023) 142 (Supplement 1): 4647.

https://doi.org/10.1182/blood-2023-180699

Published: 2023

Journal Articles

Real-World Outcome of Treatment with Single-Agent Ibrutinib in Patients with Chronic Lymphocytic Leukemia: Results from the Italian Study Evidence

Blood (2022) 140 (Supplement 1): 4178–4180.

https://doi.org/10.1182/blood-2022-166140

Published: 2022

Journal Articles

The Integration of Efficacy and Safety Outcomes Identifies the Net Clinical Benefit of Targeted Agents in Upfront Therapy of Chronic Lymphocytic Leukemia: Results of Network Meta-Analysis

Stefano Molica, David Allsup, Aaron Polliack, Diana Giannarelli

Blood (2022) 140 (Supplement 1): 9913–9914.

https://doi.org/10.1182/blood-2022-157384

Published: 2022

Journal Articles

Continuous Venetoclax in Previously Untreated Patients with Chronic Lymphocytic Leukemia and TP53 Abnormalities. a Study of the Italian Campus CLL

Blood (2022) 140 (Supplement 1): 7045–7046.

https://doi.org/10.1182/blood-2022-159334

Published: 2022

Journal Articles

Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study

Blood (2021) 138 (25): 2727–2730.

https://doi.org/10.1182/blood.2021011883

Published: 2021

Includes: Supplemental data

Journal Articles

The Use of Ibrutinib in Italian CLL Patients Treated in a Real-World Setting (EVIDENCE): A Preliminary Report

Blood (2021) 138 (Supplement 1): 4684.

https://doi.org/10.1182/blood-2021-148378

Published: 2021

Journal Articles

COVID-19 Pandemic Impact on Chronic Lymphocytic Leukemia (CLL) Patients' Preferences Towards Therapies: The Italian Experience (CHOICE Study)

Stefano Molica, Luca Laurenti, Paolo Ghia, Marta Coscia, Antonio Cuneo, Gianluca Gaidano, Francesca Mauro, Anna Maria Frustaci, Daniele Vallisa, Fabrizio Pane, Giuliana Gualberti, Emilia Iannella, Paola Finsinger, Morena Caira, Paolo Sportoletti

Blood (2021) 138 (Supplement 1): 4690.

https://doi.org/10.1182/blood-2021-148308

Published: 2021

Journal Articles

An Observational Study on Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax-Based Regimens Outside Clinical Trials in Italy (GIMEMA CLL1920)

Blood (2021) 138 (Supplement 1): 3746.

https://doi.org/10.1182/blood-2021-148696

Published: 2021

Journal Articles

A Clue to Better Select Chronic Lymphocytic Leukemia Patients with Optimal Response to BNT162b2 mRNA COVID-19 Vaccine

Stefano Molica, Diana Giannarelli, Mirella Lentini, Daniela Zappala, Daniela Loiacono, Valentina Gianfelici, Giuseppina Panduri, Pasquale Minchella, Francesco Talarico, Luciano Levato

Blood (2021) 138 (Supplement 1): 3740.

https://doi.org/10.1182/blood-2021-149104

Published: 2021

Journal Articles

The Accuracy of the International Myeloma Working Group Frailty Score in Capturing Health-Related Quality of Life Profile of Patients with Relapsed Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 115.

https://doi.org/10.1182/blood-2021-145977

Published: 2021

Journal Articles

Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'

Francesca Romana Mauro, MD PhD, Gianluigi Reda, MD, Valentina Arena, MS, Livio Trentin, MD, Marta Coscia, MD PhD, Paolo Sportoletti, MD, Luca Laurenti, MD, Gianluca Gaidano, Roberto Marasca, MD, Lorella Orsucci, MD, Roberta Murru, MD, Caterina Stelitano, Fiorella Ilariucci, MD, Donato Mannina, MD, Massimo Massaia, MD, Gian Matteo Rigolin, Lydia Scarfo, Monia Marchetti, MD, Luciano Levato, MD, Monica Tani, MD, Annalisa Arcari, MD, Gerardo Musuraca, MD, Marina Deodato, Piero Galieni, Catello Califano, MD, Daniela Gottardi, MD, Anna Marina Liberati, MD, Daniela Pietrasanta, MD, Stefano Molica, MD, Ramona Cassin, MD, Andrea Visentin, MDPhD, Candida Vitale, MDPhD, Gianfranco Lapietra, MD, Irene Della Starza, PhD, Maria Stefania De Propris, PhD, Sara Raponi, PhD, Mauro Nanni, PhD, Ilaria Del Giudice, MD PhD, Giorgia Giuliani, PhD, Marco Vignetti, MD, Anna Guarini, PhD, Francesco Albano, Antonino Neri, MD, Antonio Cuneo, MD, Robin Foà, MD

Blood (2020) 136 (Supplement 1): 47–49.

https://doi.org/10.1182/blood-2020-135922

Published: 2020

Journal Articles

Retrospective Real-Life Comparison of Obinutuzumab Plus Chlorambucil Versus Ibrutinib in Previously Untreated and Unfit Patients with Chronic Lymphocytic Leukemia without TP53 Disruptions. Interim Results from the Italian CLL Campus

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136883

Published: 2020

Journal Articles

Efficacy of Idelalisib and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Treated Outside of Clinical Trial. a Report of the Gimema Group

Gian Matteo Rigolin, Annamaria Frustaci, Alfonso Piciocchi, MS, Andrea Visentin, MDPhD, Orsola Vitagliano, Marta Coscia, MD PhD, Lucia Farina, Gianluca Gaidano, Roberta Murru, MD, Marzia Varettoni, Luca Arcaini, Francesca Cibien, MD, Rossella Paolini, Paolo Sportoletti, MD, Daniela Pietrasanta, MD, Anna Lia Molinari, MD, Francesca M. Quaglia, Luca Laurenti, MD, Roberto Marasca, MD, Monia Marchetti, MD, Annalisa Chiarenza, MD PhD, Francesca Romana Mauro, MD PhD, Omar Perbellini, Donato Mannina, MD, Rosaria Sancetta, MD, Attilio Olivieri, MD, Stefano Molica, MD, Fabrizio Pane, MD, Caterina Patti, MD, Fiorella Iliariucci, Alessandro Gozzetti, Catello Califano, MD, Piero Galieni, Accursio Fabio Augello, MD, Daniele Vallisa, MD, Francesca Cura, Enrico Crea, Paola Fazi, MD, Giulia Zamprogna, MD, Mauro Krampera, MD PhD, Livio Trentin, MD, Felicetto Ferrara, MD, Massimo Gentile, Marco Montillo, Robin Foà, MD, Antonio Cuneo, MD

Blood (2020) 136 (Supplement 1): 23–25.

https://doi.org/10.1182/blood-2020-134669

Published: 2020

Journal Articles

Comparison between Time-Limited,Venetoclax-Based and Continuous Bruton Thyrosine Kinase Inhibitors-Based Therapy in the Upfront Treatment of Chronic Lymphocytic Leukemia (CLL):a Systematic Review and Network Meta-Analysis

Stefano Molica, MD, Diana Giannarelli, PhD, Emili Montserrat, MD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-137405

Published: 2020

Journal Articles

Poor Prognosis of Multiple Myeloma Predicted By High Levels of Circulating Plasma Cells Is Independent from Other High-Risk Features but Is Modulated By the Achievement of Minimal Residual Disease Negativity

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-137075

Published: 2020

Journal Articles

Upfront Therapy with Ibrutinib Results in a Longer Progression-Free Survival Independently of IGHV Mutational Status and Del(11q) in CLL Patients. Results of a Comprehensive Review and Meta-Analysis

Stefano Molica, MD, Diana Giannarelli, PhD, Luciano Levato, MD, Emili Montserrat, MD

Blood (2019) 134 (Supplement_1): 5469.

https://doi.org/10.1182/blood-2019-123596

Published: 2019

Journal Articles

A Scoring System to Predict the Risk of Atrial Fibrillation in Chronic Lymphocytic Leukemia and Its Validation in a Cohort of Ibrutinib-Treated Patients

Blood (2018) 132 (Supplement 1): 3118.

https://doi.org/10.1182/blood-2018-99-114899

Published: 2018

Journal Articles

The Magnitude of Improvement in Progression-Free Survival with Targeted Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia Based on Genetic Risk: A Systematic Review and Meta-Analysis

Stefano Molica, MD, Diana Giannarelli, PhD, Rosana Mirabelli, MD, Luciano Levato, Tait D. Shanafelt, MD

Blood (2018) 132 (Supplement 1): 5568.

https://doi.org/10.1182/blood-2018-99-112580

Published: 2018

Journal Articles

Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib within a Named Patient Program (NPP) in Italy. a Real-Life Retrospective Study

Blood (2018) 132 (Supplement 1): 3147.

https://doi.org/10.1182/blood-2018-99-118280

Published: 2018

NARROW

Prevalence of BTK and PLCG2 Mutations in BTK Inhibitor Treated CLL Patients Who Experience Disease Progression: A Meta-Analysis

Targeted Agents in Chronic Lymphocytic Leukemia (CLL): Advancements in Overall Survival Outcomes?

Real-World Outcome of Treatment with Single-Agent Ibrutinib in Patients with Chronic Lymphocytic Leukemia: Results from the Italian Study Evidence

The Integration of Efficacy and Safety Outcomes Identifies the Net Clinical Benefit of Targeted Agents in Upfront Therapy of Chronic Lymphocytic Leukemia: Results of Network Meta-Analysis

Continuous Venetoclax in Previously Untreated Patients with Chronic Lymphocytic Leukemia and TP53 Abnormalities. a Study of the Italian Campus CLL

Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study

The Use of Ibrutinib in Italian CLL Patients Treated in a Real-World Setting (EVIDENCE): A Preliminary Report

COVID-19 Pandemic Impact on Chronic Lymphocytic Leukemia (CLL) Patients' Preferences Towards Therapies: The Italian Experience (CHOICE Study)

An Observational Study on Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax-Based Regimens Outside Clinical Trials in Italy (GIMEMA CLL1920)

A Clue to Better Select Chronic Lymphocytic Leukemia Patients with Optimal Response to BNT162b2 mRNA COVID-19 Vaccine

The Accuracy of the International Myeloma Working Group Frailty Score in Capturing Health-Related Quality of Life Profile of Patients with Relapsed Refractory Multiple Myeloma

Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'

Retrospective Real-Life Comparison of Obinutuzumab Plus Chlorambucil Versus Ibrutinib in Previously Untreated and Unfit Patients with Chronic Lymphocytic Leukemia without TP53 Disruptions. Interim Results from the Italian CLL Campus

Efficacy of Idelalisib and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Treated Outside of Clinical Trial. a Report of the Gimema Group

Comparison between Time-Limited,Venetoclax-Based and Continuous Bruton Thyrosine Kinase Inhibitors-Based Therapy in the Upfront Treatment of Chronic Lymphocytic Leukemia (CLL):a Systematic Review and Network Meta-Analysis

Poor Prognosis of Multiple Myeloma Predicted By High Levels of Circulating Plasma Cells Is Independent from Other High-Risk Features but Is Modulated By the Achievement of Minimal Residual Disease Negativity

Upfront Therapy with Ibrutinib Results in a Longer Progression-Free Survival Independently of IGHV Mutational Status and Del(11q) in CLL Patients. Results of a Comprehensive Review and Meta-Analysis

A Scoring System to Predict the Risk of Atrial Fibrillation in Chronic Lymphocytic Leukemia and Its Validation in a Cohort of Ibrutinib-Treated Patients

The Magnitude of Improvement in Progression-Free Survival with Targeted Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia Based on Genetic Risk: A Systematic Review and Meta-Analysis

Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib within a Named Patient Program (NPP) in Italy. a Real-Life Retrospective Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only